Dyadic International (DYAI) FCF Margin (2018 - 2026)
Dyadic International (DYAI) posted FCF Margin of 176.72% for Q1 2026, down 260.53% sequentially from 110.09% in Q4 2025, and up 31867.0% YoY from N/an in Q1 2025.
Dyadic International (DYAI) FCF Margin (2018 - 2026) Analysis & Trends
Dyadic International has reported FCF Margin for 9 years, with the latest figure at 176.72% in Q1 2026.
- Quarterly FCF Margin rose 31867.0% year-over-year to 176.72% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 349.73% (down 21436.0% YoY) and the FY2025 annual result came in at 621.87%, down 50815.0% from the prior year.
- FCF Margin slipped to 176.72% in Q1 2026 per DYAI's latest filing, from 110.09% in the prior quarter.
- Over five years, FCF Margin peaked at 110.09% in Q4 2025 and troughed at 509.04% in Q2 2024.
- A 5-year average of 226.98% and a median of 201.93% in 2022 frame the typical range for FCF Margin.
- The widest YoY moves for FCF Margin: up 61497 bps in 2022, down 20325982 bps in 2022.
- Over 5 years, FCF Margin stood at 226.13% in 2022, then surged by 41 bps to 134.5% in 2023, then surged by 37 bps to 85.2% in 2024, then surged by 229 bps to 110.09% in 2025, then plunged by 261 bps to 176.72% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 176.72%, 110.09%, and 159.05% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Dyadic International | 20.18 Mn | 20.18 Mn | - | -176.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -176.72% |
| Dec 31, 2025 | 110.09% |
| Sep 30, 2025 | -159.05% |
| Jun 30, 2025 | -13.45% |
| Mar 31, 2025 | -495.39% |
| Dec 31, 2024 | -85.20% |
| Sep 30, 2024 | -10.27% |
| Jun 30, 2024 | -509.04% |
| Mar 31, 2024 | -332.61% |
| Dec 31, 2023 | -134.50% |
| Sep 30, 2023 | -494.06% |
| Jun 30, 2023 | -197.66% |
| Mar 31, 2023 | -223.60% |
| Dec 31, 2022 | -226.13% |
| Sep 30, 2022 | -201.93% |
| Jun 30, 2022 | -269.59% |
| Mar 31, 2022 | -439.58% |
| Dec 31, 2021 | -841.09% |
| Sep 30, 2021 | -625.48% |
| Jun 30, 2021 | 202,990.23% |